ArticleClinical, cosmetic and investigational dermatology2025
Risk Factors for Drug-Induced Acute Generalized Exanthematous Pustulosis(AGEP) from 2004 to 2024: A Real-World Study Based on the FAERS.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The cutaneous mirror: leveraging drug-induced skin phenotypes as early visual risk signals for systemic toxicity, a comprehensive review.Frontiers in drug safety and regulation · 2026Review
- Sex-specific adverse event profiles of PDE4 inhibitors: a comparative big-data pharmacovigilance study of apremilast, crisaborole, and roflumilast in FAERS (2004-2025).Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute Generalized Exanthematous Pustulosis (AGEP) is a rare but potentially life-threatening cutaneous adverse drug reaction. Due to its poor clinical outcomes and unclear pathogenesis, this study aimed to systematically evaluate the drug-related risk factors for AGEP using data from the FDA Adverse Event Reporting System (FAERS). Methods: This real-world, retrospective pharmacovigilance study analyzed all AGEP-related reports submitted to the FAERS database between Q1 2004 and Q4 2024. Disproportionality analysis was performed using reporting odds ratios (RORs), with Bonferroni-adjusted p-values to identify high-risk drugs. Drugs identified by univariate analysis were further evaluated through LASSO regression and multivariable logistic regression to determine risk factors associated with AGEP. Results: A total of 6,880 AGEP cases were identified, with a predominance of female patients (54.5%) and a median age of 59 years. Disproportionality analysis revealed 148 drugs with a significant signal for AGEP, mainly including antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and antivirals. LASSO and multivariate logistic regression identified 17 drugs as risk factors for AGEP, including ceftriaxone (OR = 49.87), pantoprazole (OR = 31.39), and hydroxychloroquine (OR = 28.38). The model showed moderate predictive accuracy with an AUC of 0.69. Conclusion: This study identified multiple drug classes significantly associated with AGEP using FAERS-based adverse event data. The findings highlight a higher susceptibility in middle-aged and younger populations and underscore the importance of enhanced monitoring for high-risk medications. Given the inherent limitations of spontaneous reporting systems, further prospective studies are needed to confirm these associations and explore underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.